• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol 2019;76:69-70: Towards Biomarker-Informed Management of Muscle-Invasive Bladder Cancer.

作者信息

Mouw Kent W, Miyamoto David T, Efstathiou Jason A

机构信息

Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital Cancer Center, Boston, MA, USA.

出版信息

Eur Urol. 2019 Jul;76(1):71-72. doi: 10.1016/j.eururo.2019.03.009. Epub 2019 Mar 23.

DOI:10.1016/j.eururo.2019.03.009
PMID:30910345
Abstract
摘要

相似文献

1
Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol 2019;76:69-70: Towards Biomarker-Informed Management of Muscle-Invasive Bladder Cancer.作者回复：关于阿南雅·乔杜里、彼得·J·霍斯金。肌层浸润性膀胱癌的预测生物标志物：寻找圣杯仍在继续。《欧洲泌尿外科杂志》2019年；76卷：69 - 70页：迈向基于生物标志物的肌层浸润性膀胱癌管理
Eur Urol. 2019 Jul;76(1):71-72. doi: 10.1016/j.eururo.2019.03.009. Epub 2019 Mar 23.
2
Reply from Authors re: Girish S. Kulkarni, Zachary Klaassen. Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details? Eur Urol 2017;72:488-9: Using the National Cancer Data Base to Compare Treatment Modalities for Localized Muscle-invasive Bladder Cancer.作者回复：关于Girish S. Kulkarni、Zachary Klaassen。利用人群水平数据，三联疗法治疗肌层浸润性膀胱癌劣于根治性膀胱切除术：（缺乏）细节中有证据吗？《欧洲泌尿外科杂志》2017年；72卷：488 - 489页：利用国家癌症数据库比较局限性肌层浸润性膀胱癌的治疗方式
Eur Urol. 2017 Oct;72(4):489-491. doi: 10.1016/j.eururo.2017.05.021. Epub 2017 May 30.
3
Re: Günter Niegisch, Anja Lorch, Michael J. Droller, Hugh J. Lavery, Kristian D. Stensland, Peter Albers. Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit? Eur Urol 2013;64:355-7.回复：京特·尼吉施、安雅·洛尔希、迈克尔·J·德罗拉、休·J·拉弗里、克里斯蒂安·D·斯滕斯兰德、彼得·阿尔伯斯。肌层浸润性膀胱癌患者的新辅助化疗：哪些患者获益？《欧洲泌尿外科杂志》2013年；64卷：355 - 357页
Eur Urol. 2014 Jan;65(1):e8-9. doi: 10.1016/j.eururo.2013.08.016. Epub 2013 Aug 17.
4
Reply from authors re: Marko Babjuk. Second resection for non-muscle-invasive bladder carcinoma: current role and future perspectives. Eur Urol 2010;58:191-2 and Giacomo Novara, Vincenzo Ficarra. Does routine second transurethral resection affect the long-term outcome of patients with T1 bladder cancer? Why a flawed randomized controlled trial cannot address the issue. Eur Urol 2010;58:193-4.作者回复：关于马尔科·巴布朱克。非肌层浸润性膀胱癌的二次切除术：当前作用及未来展望。《欧洲泌尿外科杂志》2010年；58卷：191 - 192页 以及 贾科莫·诺瓦拉、文森佐·菲卡拉。常规二次经尿道切除术是否会影响T1期膀胱癌患者的长期预后？为何一项有缺陷的随机对照试验无法解决该问题。《欧洲泌尿外科杂志》2010年；58卷：193 - 194页。
Eur Urol. 2010 Aug;58(2):195-6. doi: 10.1016/j.eururo.2010.04.029. Epub 2010 May 8.
5
Re: Richard J. Sylvester, Willem Oosterlinck. An immediate instillation after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: has the evidence changed? Eur Urol 2009;56;43-5.回复：理查德·J·西尔维斯特、威廉·奥斯特林克。非肌层浸润性膀胱癌经尿道膀胱肿瘤切除术后即刻灌注：证据有变化吗？《欧洲泌尿外科杂志》2009年；56卷；43 - 5页
Eur Urol. 2010 Mar;57(3):e28-9; author reply e30. doi: 10.1016/j.eururo.2009.11.026. Epub 2009 Nov 17.
6
Re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4.回复：金莫·凯图宁、彼得·J·博斯特罗姆、塔娅·拉米宁等。使用条件重编程的患者来源细胞进行膀胱癌个性化药物敏感性筛查。《欧洲泌尿外科杂志》2019年；76卷：430 - 4页
Eur Urol. 2019 Nov;76(5):e135-e136. doi: 10.1016/j.eururo.2019.07.044. Epub 2019 Aug 14.
7
Re: Ben J. Challacombe, Bernard H. Bochner, Prokar Dasgupta, et al. The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. Eur Urol 2011;60:767-75.
Eur Urol. 2012 Apr;61(4):e29; author reply e30. doi: 10.1016/j.eururo.2011.12.015. Epub 2011 Dec 21.
8
Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues.肌肉浸润性膀胱癌的预测生物标志物：寻找圣杯的征程仍在继续。
Eur Urol. 2019 Jul;76(1):69-70. doi: 10.1016/j.eururo.2019.01.040. Epub 2019 Feb 4.
9
Reply from authors re: Urs E. Studer, Laurence Collette. Robot-assisted cystectomy: does it meet expectations? Eur Urol 2010;58:203-4.作者回复：关于乌尔兹·E·施图德、劳伦斯·科莱特。机器人辅助膀胱切除术：是否符合预期？《欧洲泌尿外科杂志》2010年；58卷：203 - 204页。
Eur Urol. 2010 Aug;58(2):204-6. doi: 10.1016/j.eururo.2010.06.021. Epub 2010 Jun 15.
10
Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60: Methodological Issues to Avoid Misinterpretation.回复：尼古拉斯·J·贾卡洛内、威廉·U·希普利、丽贝卡·H·克莱曼等。肌肉浸润性膀胱癌患者膀胱保留三联疗法的长期疗效：麻省总医院经验的最新分析。《欧洲泌尿外科杂志》2017年；71:952 - 60：避免误解的方法学问题。
Eur Urol. 2017 Sep;72(3):e63. doi: 10.1016/j.eururo.2017.06.008. Epub 2017 Jun 23.

引用本文的文献

1
Molecular subtyping, tumor infiltration, and trimodal therapy for muscle-invasive bladder cancer: more questions than answers.肌肉浸润性膀胱癌的分子亚型、肿瘤浸润及三联疗法：问题多于答案
Transl Androl Urol. 2019 Jul;8(Suppl 3):S325-S328. doi: 10.21037/tau.2019.05.12.
2
Therapy affected by tumour microenvironment.治疗受肿瘤微环境影响。
Nat Rev Urol. 2019 Apr;16(4):206. doi: 10.1038/s41585-019-0160-z.